In the db/db mouse model, having an obese phenotype in addition to hyperglycemia, dyslipidemia, and insulin resistance, MYO supplementation improved blood glucose levels, reduced insulin levels, and reduced triglyceride and total cholesterol levels, achieving results comparable to those obtained in metformin-treated mice. Here, INS is linked to metabolic syndrome.